Cancer Research Cancer Epigenetics  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pan, Q.
Right arrow Articles by Merajver, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pan, Q.
Right arrow Articles by Merajver, S. D.
[Cancer Research 66, 9379-9384, October 1, 2006]
© 2006 American Association for Cancer Research


Priority Reports

Targeted Disruption of Protein Kinase C{varepsilon} Reduces Cell Invasion and Motility through Inactivation of RhoA and RhoC GTPases in Head and Neck Squamous Cell Carcinoma

Quintin Pan1,3, Li Wei Bao1, Theodoros N. Teknos2,3 and Sofia D. Merajver1,3

1 Division of Hematology and Oncology, Department of Internal Medicine, 2 Department of Otolaryngology, and 3 Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, Michigan

Requests for reprints: Quintin Pan, Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI 48109. Phone: 734-647-3408; Fax: 734-615-2719; E-mail: qpan{at}med.umich.edu.

Over 70% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced stage III and IV disease. In spite of aggressive therapy, locoregional disease recurs in 60% and metastatic disease develops in 15% to 25% of patients causing a major decline in quality and length of life. Therefore, there is a need to identify and understand genes that are responsible for inducing an aggressive HNSCC phenotype. Evidence has shown that protein kinase C (PKC) {varepsilon} is a transforming oncogene and may play a role in HNSCC progression. In this study, we determine the downstream signaling pathway mediated by PKC{varepsilon} to promote an aggressive HNSCC phenotype. RNA interference knockdown of PKC{varepsilon} in UMSCC11A and UMSCC36, two highly invasive and motile HNSCC cell lines with elevated endogenous PKC{varepsilon} levels, resulted in cells that were significantly less invasive and motile than the small interfering RNA–scrambled control transfectants; 51 ± 5% (P < 0.006) and 49 ± 3% (P < 0.010) inhibition in invasion and 69 ± 1% (P < 0.0005) and 66 ± 3% (P < 0.0001) inhibition in motility, respectively. PKC{varepsilon}-deficient UMSCC11A clones had reduced levels of active and serine-phosphorylated RhoA and RhoC. Moreover, constitutive active RhoA completely rescued the invasion and motility defect, whereas constitutive active RhoC completely rescued the invasion and partially rescued the motility defect of PKC{varepsilon}-deficient UMSCC11A clones. These results indicate that RhoA and RhoC are downstream of PKC{varepsilon} and critical for PKC{varepsilon}-mediated cell invasion and motility. Our study shows, for the first time, that PKC{varepsilon} is involved in a coordinated regulation of RhoA and RhoC activation, possibly through direct post-translational phosphorylation. (Cancer Res 2006; 66(19): 9379-84)




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
M. Islam, G. Lin, J. C. Brenner, Q. Pan, S. D. Merajver, Y. Hou, P. Kumar, and T. N. Teknos
RhoC Expression and Head and Neck Cancer Metastasis
Mol. Cancer Res., November 1, 2009; 7(11): 1771 - 1780.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Xiao, M. Eto, and M. G. Kazanietz
ROCK Mediates Phorbol Ester-induced Apoptosis in Prostate Cancer Cells via p21Cip1 Up-regulation and JNK
J. Biol. Chem., October 23, 2009; 284(43): 29365 - 29375.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Bao, M. A. Gorin, M. Zhang, A. C. Ventura, W. C. Pomerantz, S. D. Merajver, T. N. Teknos, A. K. Mapp, and Q. Pan
Preclinical Development of a Bifunctional Cancer Cell Homing, PKC{varepsilon} Inhibitory Peptide for the Treatment of Head and Neck Cancer
Cancer Res., July 15, 2009; 69(14): 5829 - 5834.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. K. Basu, L. Kole, M. Basu, K. Chakraborty, P. S. Mitra, and I. S. Owens
The Major Chemical-detoxifying System of UDP-glucuronosyltransferases Requires Regulated Phosphorylation Supported by Protein Kinase C
J. Biol. Chem., August 22, 2008; 283(34): 23048 - 23061.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K.-M. Bae, H. Wang, G. Jiang, M. G. Chen, L. Lu, and L. Xiao
Protein Kinase C{varepsilon} Is Overexpressed in Primary Human Non-Small Cell Lung Cancers and Functionally Required for Proliferation of Non-Small Cell Lung Cancer Cells in a p21/Cip1-Dependent Manner
Cancer Res., July 1, 2007; 67(13): 6053 - 6063.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.